Background
==========

Numerous studies have demonstrated that intensive control of blood glucose reduces the development and progression of vascular complications in diabetes \[[@B1]-[@B7]\]. The balance of randomized trial evidence suggests intensive glucose control reduces risk for some cardiovascular disease outcomes \[[@B8]\], even while there are notable exceptions to this pattern \[[@B1],[@B9],[@B10]\].

However, even patients who are placed on intensive treatment often do not achieve adequate control, a result observed in both clinical trials and observational studies \[[@B11]-[@B14]\]. One potential reason for inadequate control is the experience or fear of hypoglycaemia, which can lead to non-adherence or non persistence to treatment, and other behaviours to raise blood glucose, such as increased consumption of carbohydrates, avoidance of exercise, and reducing the dose of antihyperglycaemic medications \[[@B15]-[@B18]\]. Further, physicians see hypoglycaemia as a limiting factor in how aggressively they can use therapies such as insulin (associated with hypoglycaemia) to treat type 2 diabetes (T2D) \[[@B19]\].

The relationship between hypoglycaemic events (HEs) and outcomes in patients with T2D has been investigated in several recent studies, including a cross-sectional survey of 2,074 patients with T2D in the United States (US) on oral antihyperglycaemic medication \[[@B20]\]. Those who reported symptoms of hypoglycaemia at least 'some of the time' on the hypoglycaemia items of the Diabetes Symptom Measure \[[@B21]\] were less likely to be at their treatment goal for glycosylated haemoglobin (HbA1c), as well as less likely to know their HbA1c.

Another large (n = 1,984) survey of US patients with T2D found worse self-reported health status as severity of HE increased from mild (no interruption of activities) through moderate, severe, and very severe (required medical attention) \[[@B22]\]. The same study found a relationship between frequency of HEs and increased worry about hypoglycaemia. Likewise, linking patient surveys with healthcare claims data demonstrates that patients with T2D treated with pharmacotherapy who experience HEs have higher medical costs, more fear of hypoglycaemia, and impaired health status relative to patients without HEs \[[@B23]\].

Further, a multi-country study in Asia (n = 2257) assessed the relationship between experience of symptoms of hypoglycaemia and HbA1c, health status, and worry about hypoglycaemia \[[@B24]\]. As in the studies above, hypoglycaemia symptoms were associated with worse health status and more worry about hypoglycaemia. This study also measured HbA1c, and an unadjusted analysis showed 0.24% *lower* average HbA1c among those with HE in the 6 months prior. Patient-perceived symptom severity was not associated with differences in HbA1c, though the pattern of means suggests more severe HE may be associated with higher HbA1c.

Despite these recent additions to the literature, gaps remain, especially within individual countries. It is important to understand how blood glucose levels, particularly the longer-term blood glucose levels reflected in HbA1c, are related to the experience of HEs, a relationship seldom assessed. Therefore, the objective of current study was to assess the link between HEs, HbA1c, patient-reported outcomes, and healthcare resource use among patients with T2D in the United Kingdom (UK).

Methods
=======

Potential respondents were identified through the 2011 5EU National Health and Wellness Survey (NHWS) and the diabetes chronic ailment panel of Light Speed Research in the UK. The 5EU NHWS is a proprietary survey of adults (≥18 years) conducted by Kantar Health in France, Germany, Italy, Spain, and UK, which collects data approximately every 18 months to provide timely patient-reported information on a broad range of health conditions. The UK portion of the 5EU NHWS survey includes 15,000 respondents representative of the UK population in terms of age and gender. The Light Speed chronic ailment panel consists of individuals who have previously indicated they suffer from diabetes. All panel participants were originally sourced from a general (i.e., not healthcare-specific) internet survey panel whose members are recruited through opt-in emails, co-registration with panel partners, e-newsletter campaigns, online banner placements, and both internal and external affiliate networks. All panelists explicitly consented to become panel members, registered through unique email addresses, and completed in-depth demographic registration profiles.

Panelists from the Light Speed chronic ailment group and respondents to the 5EU NHWS survey residing in the UK who indicated that they had diabetes were sent an invitation email with a link to the informed consent of the survey (n = 7,144). Those who gave consent (n = 3,224; 45%) were then screened for a physician diagnosis of T2D (n = 2,396), and current use of a prescription medicine for their T2D (n = 2,071). In order to ensure adequate numbers of insulin users, a quota of 300 respondents using insulin was included, which resulted in 295 T2D patients using only oral medication being excluded from the survey. The remaining patients (n = 1,776) were directed to the baseline questionnaire.

The study was designed as a longitudinal survey with six assessment points from February 2012-July 2012, each separated by four weeks. Respondents were informed that they would receive a small incentive for completion of each assessment point, either in the form of points that could be exchanged for merchandise or a monetary payment. Incentives increased from approximately £2.50 for the baseline survey to £12.75 for the final assessment to discourage attrition. Respondents were notified of the availability of the questionnaire via email at the opening of each assessment point and had one week to complete the questionnaire, and all those who completed the baseline were invited to participate in each follow-up. Up to four reminder emails were sent over the course of the week the survey was available. However, attrition over the duration of the study resulted in only 34% (n = 451) of the baseline sample reporting at the last follow-up, and only 12% (n = 155) of baseline respondents completed all follow-up waves. Therefore, the current study primarily focuses on cross-sectional analysis of baseline data.

The study protocol and questionnaire was approved by Essex IRB, a commercial IRB based in the United States.

Measures
--------

All measures were by self-report with the exception of geographic region, which was extracted from survey panel records. Demographic characteristics collected included age, gender, employment status, annual household income, and UK region. Height and weight were used to calculate body mass index (BMI), and respondents indicated whether they currently smoke cigarettes, as well as the number of days they exercised "vigorously" in the past 30. Respondents were also asked to indicate whether they had been diagnosed with various chronic conditions, which were used to calculate the Charlson comorbidity index (CCI) \[[@B25]\].

Questions regarding their experience with HEs included whether they had ever experienced a HE, the number of events they had experienced in the prior six months, and the number of HEs they had experienced in the prior four weeks. These were categorised by the level of assistance needed; self-managed, requiring assistance from someone else (not a healthcare professional), and requiring assistance from a medical professional.

Those who reported ever experiencing a HE answered questions characterizing the most recent event. These included how the event was detected (symptoms confirmed by a blood glucose reading, symptoms not confirmed with a blood glucose reading, and a low blood glucose reading in the absence of symptoms), the perceived trigger of the event, the assistance required, the circumstances (what they were doing at the time) and what actions they (or someone else) took in response to the HE.

Glycaemic control was assessed through the most recent self-reported HbA1c. Respondents could use either percentage or mmol/mol formats (here converted to percentage for reporting). Those who could not provide an HbA1c reading were presented with a series of ranges of HbA1c values and asked to indicate the range (and approximate date) of their most recent results. Because HbA1c is only typically assessed between one and four times per year in the UK, values provided at the first follow-up survey were used to supplement the values provided at baseline for those who did not provide a baseline value.

Multiple existing patient-reported outcome questionnaires were administered as part of the survey:

Health status was assessed using the EQ-5D questionnaire \[[@B26]\]; a widely used preference-based, generic (as opposed to disease-specific) questionnaire. The questionnaire consists of 2 parts -- a population-weighted health state index score and a self-perceived current health score. Only the health state index score was used in this study. This score is calculated based on responses to 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and then weighted using UK population weights to provide a single value on a scale from −0.594 to1 with higher scores indicating better health utility (negative values indicate a health state worse than dead).

The Work Productivity and Activity Impairment (WPAI) questionnaire \[[@B27]\] was used to measure impairment to work productivity and the activities of daily living. Four subscales (absenteeism, presenteeism, overall work impairment, and activity impairment) are generated in the form of percentages (0 to 100%), with higher values indicating greater impairment during the preceding seven days. All respondents completed the general health version, which queries work and activity impairment due to general health. Those reporting a hypoglycaemic event in the preceding seven days also completed the Specific Health Problem version to assess impairment due to hypoglycaemia.

Treatment satisfaction was measured using the Diabetes Medication Satisfaction Tool (DMSAT). The DMSAT \[[@B28]\] measures satisfaction with the patient's diabetes medications regimen. The instrument consists of 16 items which create 4 subscales (3 items for wellbeing, 3 items for medical control, 5 items for lifestyle, and 5 items for convenience) and a total score. Responses are summed and converted to a score from 0 to 100 for each subscale and overall, with higher scores representing more satisfaction. For the purposes of this study, only the overall score was used.

Adherence to medication was measured using the Morisky medication adherence scale (MMAS) \[[@B29],[@B30]\].The MMAS is a generic self-reported, medication-taking behaviour scale, consisting of four items which are summed to give a range of scores from high adherence (0) to low adherence (4). After discussion with the scale author, the scale was modified, creating one version assessing oral antidiabetic medication and a second assessing insulin (administered only to patients taking insulin).

The Hypoglycaemia Fear Survey, revised (HFS-II) was used to measure fear of hypoglycaemia \[[@B31]\]. This is a 33-item questionnaire with two subscales that measure 1) behaviours to avoid hypoglycaemia and its negative consequences and 2) worries about hypoglycaemia and its negative consequences. Responses are made on a 5-point Likert scale where 0 = Never and 4 = Always. The behaviour, worry, and total scores were all included in analyses. Behaviour subscale items include items that would not necessarily contribute to poorer glycaemic control (e.g., avoiding being alone) and five behaviors that would: eating large snacks, keeping blood glucose (BG) above 150, keeping BG higher than normal in social situations, keeping BG higher than normal during important activities, and reducing insulin dose. These items were included in the behavioral subscale and total scale scores, but also analyzed separately, dichotomized as never engaging in that behaviour versus engaging in the behaviour during the recall period. Though the standard recall period for the HFS-II is six months, the measure was modified to better suit the design of the current study to include a four-week recall period after discussion with the scale author.

In addition, respondents were asked to indicate the number of times they visited different types of healthcare providers in relation to their diabetes care during the four weeks prior as a measure of healthcare resource use. These included the physician who primarily manages their T2D (may be primary or secondary care), other physicians, and other providers (nurses, dieticians, podiatrists, etc.). These were combined with the primary physician visits to provide a count of the total provider visits. Another item queried the number of times the respondent was hospitalized in the preceding four weeks.

Statistical analysis
--------------------

The total sample was characterized using mean and standard deviation for continuous variables and frequency and percentages for categorical variables. These were followed with a comparison between the group of patients who reported having a hypoglycaemic event in the four weeks preceding baseline and the group who did not report an event, with comparisons planned for the outcomes listed above. For continuous variables, an independent groups t-statistic was used for the comparison (with a Welch-Satterthwaite approximation to the degrees of freedom when the homogeneity assumption violated). A chi-square test was used for categorical variables. P-values \< 0.05 were considered statistically significant. No adjustment for multiplicity was made.

Results
=======

A total of 1,329 respondents completed the baseline survey; follow-up surveys were completed by 836, 759, 765, 511, and 451 respondents, respectively. Demographics and general health characteristics are presented in Table [1](#T1){ref-type="table"}. Consistent with the T2D population, the sample was predominantly late middle age, male, and overweight. All the regions of the UK were represented, roughly in proportion to the general population. Clinical characteristics are presented in Table [2](#T2){ref-type="table"}. Respondents on average reported diabetes duration of 9.6 years, and most were free of complications. The majority were using only oral antihyperglycaemic medication. Of those who provided a value for HbA1c (29.6%), the mean value was 7.3%. When considering both those who provided a value for HbA1c (n = 393) and those who could not provide a value but selected their HbA1c from a range (n = 495), 32.6% reported an HbA1c of 7.0% or below. An additional 33.2% did not provide either an exact or approximate HbA1c value.

###### 

Demographics and general health characteristics of the sample (n = 1,329)

                            **n/mean**           **%/SD**
  ------------------------- -------------------- ----------
  Demographics                                    
  Age                       58.8                 10.9
  Female                    534                  40.2%
  Employed                  448                  33.7%
  Annual household Income                         
                             \<30,000£           846
                             ≥30,000£            330
                             Decline to answer   153
  General health                                  
  BMI (continuous)          31.9                 6.4
  BMI (categories)                                
                             Underweight         8
                             Normal weight       119
                             Overweight          362
                             Obese               683
                             Decline to answer   157
  Exercised\*               599                  45.1%
  Currently smoke           158                  11.9%
  CCI                       1.6                  1.5

\*Note: Exercised indicates exercising "vigorously" at least once for 20 minutes during the preceding month. CCI: Charlson comorbidity index.

###### 

Diabetes characteristics of sample (n = 1,329)

                                                    **n/mean**   **%/SD**
  ------------------------------------------------- ------------ ----------
  Duration of diabetes (years)                      9.6          7.0
  HbA1c (among those providing a number; n = 393)   7.25%        1.5%
  HbA1c in ranges                                                 
   Up to 6.5%                                       219          16.5%
   6.6%-7.0%                                        214          16.1%
   7.1%-7.5%                                        152          11.4%
   7.6%-8.5%                                        146          11.0%
   8.6%-9.5%                                        79           5.9%
   9.6%-10.5%                                       44           3.3%
   10.6% or above                                   34           2.6%
   Unknown                                          441          33.2%
  Medications                                                     
   Oral (OAD) only                                  971          73.1%
   Non-insulin injectable (NII) only                16           1.2%
   Insulin (IN) only                                79           5.9%
   OAD & NII                                        41           3.1%
   OAD & IN                                         174          13.1%
   NII & IN                                         7            0.5%
   OAD, NII, & IN                                   41           3.1%
  Complications                                                   
   Macular edema/diabetic retinopathy               117          8.8%
   Kidney disease                                   51           3.8%
   Foot or leg ulcer                                60           4.5%
   Neuropathic pain                                 220          16.6%
   End organ damage                                 18           1.4%
   None                                             989          74.4%

The prevalence of ≥1 HE within the 4-week period was 27.5% for the sample overall, higher among insulin users (n = 301) than those not using insulin (n = 1,028) (43.5% vs. 22.8%, p \< 0.0001).

Characteristics of most recent HE
---------------------------------

Among those experiencing ≥1 HE, most (61.2%) had symptoms of hypoglycaemia with a low blood glucose reading, but 27.7% did not test blood glucose during the most recent HE. 5.5% were only aware of their most recent event because of a blood-glucose test, and 5.5% had a normal blood glucose reading during the event they considered to be hypoglycaemic in nature.

Among those experiencing symptoms during their most recent HE, the most common were trembling/shaking (55.3%), dizziness/light-headedness (53.6%), sweating (38.6%), weakness (34.1%) and uneasiness/ill feeling (32.6%). Most patients (89.8%) reported experiencing multiple symptoms.

Most HEs were attributed to lack of timely eating or inappropriate food choices. The most commonly endorsed reasons were delayed eating (29.6%), irregular or too few carbohydrates (24.8%) and skipped meals or snacks (20.4%). Too much exercise (15.6%) and stress (13.2%) were also commonly implicated triggers. 4.6% attributed the incident to a new antidiabetic medication, and 10% of insulin users experiencing a HE indicated a miscalculation of insulin dose.

The most common circumstance for the most recent HE was while doing household jobs or shopping (22.1%), followed by relaxing (watching TV, reading; 21.5%), and just prior to eating (9.9%), during leisure/social activities (9.3%) and while sleeping (9.3%). Only 8.1% of the most recent HEs were while at work, though much of the sample was not employed. Of those employed, at work was the most commonly reported location (23.0%).

Most of the most recent HEs described were self-managed (85.2%), but 10.1% required assistance from another non-medical person and 4.7% needed medical assistance. The most typical response was to eat or drink something (76.4%) and/or take glucose tablets (21.7%), or discontinue physical activity (9.4%). Some patients began checking their blood glucose more frequently (16.8%) and (3.4%) had their doctor change their treatment regimen as a result of the most recent HE.

Outcome differences associated with HE
--------------------------------------

Comparisons between those with ≥1 HE in the prior four weeks and those without an event during the same period of time revealed numerous differences (Table [3](#T3){ref-type="table"}). Of primary interest, among the portion of the sample providing a value for HbA1c at baseline or the first follow-up survey, those with ≥1 HE in the preceding four week had significantly higher A1c values than those who did not (p \< 0.01). The EQ-5D health state index score was lower (worse) among those experiencing ≥1 HE in 4 weeks prior to the first survey relative to those without (p \< 0.0001). Differences in work impairment between the two groups were also apparent. Employed respondents who experienced ≥1 HE in the month leading to the baseline survey reported approximately double the work impairment in the prior seven days experienced by those employed respondents without ≥1 HE, an absolute difference of 18.7%. Impairment to non-work activities during the same period was also higher among those with ≥1 HE, equating to a mean absolute difference of 12.5%. Those who had experienced ≥1 HE in the past week attributed considerable impairment to the event, 24.6% overall work impairment among the employed, and 44% impairment in non-work activities (not presented).

###### 

Bivariate health outcome differences between patients reporting hypoglycaemia and patients not experiencing hypoglycaemia

                                             **Hypoglycaemia (n = 365)**   **No hypoglycaemia (n = 964)**                   
  ------------------------------------------ ----------------------------- -------------------------------- ------- ------- ----------
  HbA1c (n =139 & 254)                       7.51                          1.60                             7.11    1.39    0.0095
  EQ-5D Index (n = 360 & 953)                0.56                          0.39                             0.69    0.34    \<0.0001
  Work and activity impairment                                                                                               
   Overall work impairment (n = 141 & 270)   35.3%                         35.8%                            16.6%   25.6%   \<0.0001
   Activity impairment                       44.5%                         32.8%                            32.0%   31.7%   \<0.0001
  Treatment satisfaction                     0.67                          0.17                             0.75    0.18    \<0.0001
  Adherence to treatment                                                                                                     
   Oral medications (n = 316 & 911)          0.81                          1.01                             0.69    0.94    0.0573
   Insulin (n = 131 & 170)                   0.95                          1.25                             0.60    0.96    0.0076
  Diabetes-related healthcare resource use                                                                                   
   4-week PCP visits                         0.73                          1.05                             0.38    0.66    \<0.0001
   4-week total visits                       1.82                          2.50                             0.92    1.51    \<0.0001
   4-week hospitalizations                   0.16                          0.52                             0.06    0.31    0.0006
  Hypoglycaemia fear                                                                                                         
   Worry                                     15.60                         12.51                            6.53    9.24    \<0.0001
   Behaviour                                 17.81                         15.39                            6.58    10.95   \<0.0001
   Total                                     33.40                         25.46                            13.11   18.46   \<0.0001

Note: When fewer than the full sample are included in a comparison, sample sizes are indicated in parentheses for those experiencing hypoglycaemia and not experiencing hypoglycaemia in the four weeks prior to the survey, respectively. Lower HbA1c is associated with better outcomes and fewer complications. Higher EQ-5D scores indicate more preferred health status, with 1.0 equivalent to perfect health. Work impairment and activity impairment ranged from 0 to 100%, with lower numbers indicating less impairment. Treatment satisfaction ranges from 0 to 1.0, with higher numbers indicating grater satisfaction. Adherence to treatment ranges from 0 to 4, with higher numbers indicating less adherence. Hypoglycemia fear ranges from 0 to 72 for Worry, 0 to 60 for behaviour, and 0 to 132 for the total score, with higher scores indicating more fear of hypoglycaemia.

Satisfaction with medication and adherence to medications were also different based on the experience of ≥1 HE in the prior four weeks. Medication satisfaction was lower among those who experienced ≥1 HE in the 4 weeks prior to survey (.08 on a 0--1.0 scale; p \< 0.0001). Adherence to oral medication was only marginally lower (p = .06) in those with at ≥1 HE in the prior four weeks, and adherence to insulin was significantly lower among insulin users experiencing ≥1 HE during that time relative to insulin users who did not (p \< 0.0001).

Experience of ≥1 HE in the past month was associated with increased healthcare resource use relative to those who did not. Patients who experienced ≥1 HE visited the physician (who primarily manages their T2D) almost twice as often as those who did not. A similar increase was seen in the number of total diabetes-related healthcare visits. There were relatively few diabetes-related hospitalizations reported among either group, but the average among those reporting ≥1 HE was more than twice that of those who did not report any HEs.

Fear of hypoglycaemia was significantly higher among those experiencing ≥1 HE for the total score as well as both subscales (p \< 0.0001). Respondents with ≥1 HE reported performing a range of specific glucose-raising behaviours on the HFS-II (Table [4](#T4){ref-type="table"}).

###### 

Blood-glucose increasing behaviours in HFS-II used within last 4 weeks by experience of hypoglycaemia during that period

                                                            **Hypoglycaemia (n = 365)**   **No hypoglycaemia (n = 964)**                 
  --------------------------------------------------------- ----------------------------- -------------------------------- ----- ------- ----------
  Ate large snacks                                          283                           77.5%                            497   51.6%   \<0.0001
  Kept glucose above 150                                    225                           61.6%                            352   36.5%   \<0.0001
  Kept glucose higher than normal in social situations      199                           54.5%                            189   19.6%   \<0.0001
  Kept glucose higher than normal in important activities   205                           56.2%                            197   20.4%   \<0.0001
  Reduced insulin dose (n = 131 & 170)                      91                            69.5%                            88    51.8%   0.0021

Baseline data of those completing all surveys was explored for differences between those reporting ≥1 HE during the course of the study (n = 83) and those who did not experience HE (n = 72). This analysis included only a small and self-selected subsample of the baseline survey respondents, but is included here to facilitate hypothesis generation for future research (Table [5](#T5){ref-type="table"}). The mean difference in HbA1c averaged across each wave (0.3%) was consistent with the baseline difference, but not statistically significant. The mean EQ-5D index score for those with ≥1 HE during the study was .09 points worse that of those who completed the study without experiencing any HE, a difference which approached statistical significance (p =0.07) and would exceed the 0.07 threshold for minimally important difference \[[@B32]\]. There was greater activity impairment among the group that experienced ≥1 HE, but no significant difference in work impairment. The 8% decrement in satisfaction with diabetes medication observed in the baseline comparison was observed in the longitudinal sample. Greater use of healthcare resources was observed among those reporting ≥1 HE, although this difference was limited to the total number of provider visits. The most significant differences in the longitudinal subsample were of average scores on the HFS-II, all of which remained significantly worse (all p \<0.001), with total scores 15 points higher among those with ≥1 HE.

###### 

Average outcomes among those completing all study surveys

                                             **Hypoglycaemia (n = 83)**   **No hypoglycemia (n = 72)**                   
  ------------------------------------------ ---------------------------- ------------------------------ ------- ------- ----------
  HbA1c (LOCF; n = 53 & 37)                  7.35%                        1.68%                          7.05%   1.83%   0.4389
  Health-related quality of life                                                                                          
   EQ-5D index                               0.62                         0.35                           0.71    0.29    0.0669
  Work and activity impairment                                                                                            
   Overall work impairment                   19.6%                        21.9%                          10.8%   22.5%   0.1620
   Activity impairment                       41.2%                        29.2%                          28.9%   29.4%   0.0102
  Treatment satisfaction                     0.72                         0.16                           0.80    0.15    0.0011
  Diabetes-related healthcare resource use                                                                                
   4-week diabetes PCP visits                0.43                         0.48                           0.31    0.41    0.0948
   4-week total diabetes provider visits     1.07                         1.24                           0.69    0.88    0.0286
   4-week total hospitalizations             0.05                         0.15                           0.06    0.24    0.9661
  Hypoglycaemia fear                                                                                                      
   Worry                                     11.59                        9.72                           4.45    5.31    \<0.0001
   Behaviour                                 11.61                        11.74                          3.26    5.72    \<0.0001
   Total                                     23.19                        20.25                          7.71    9.47    \<0.0001

Note: LOCF, last observation carried forward.

Discussion
==========

The current study found that HEs are common in patients with T2D in the UK, with 23% of those using oral medication (without insulin) experiencing a HE during a four week period, while the rate among insulin users was nearly double (44%). Those who experienced ≥1 HE in the prior week attributed substantial impairment to both work and activities of daily living. Comparisons of those who experienced ≥1 HE in the four weeks prior to the survey also had worse outcomes, including health status and treatment satisfaction, more diabetes-specific healthcare resource use, greater impairment of non-work activities, and more fear of hypoglycaemia, including a greater likelihood of reporting behaviours that would raise their blood glucose levels. Insulin users who reported ≥1 HE also reported less adherence to their insulin than users who were free of HEs; the relationship between HEs and adherence was not observed in oral medications, perhaps because patients understand the potential for insulin to cause hypoglycaemia, and perhaps due to the injectable mode of administration, which is more aversive than swallowing a pill and also enables dose reduction.

Although the 0.3% difference in HbA1c is modest relative to the effect of antihyperglycaemic medications \[[@B33]\], it indicates that HEs may be predictive of higher HbA1c when linked to the results indicating HEs to be associated with behaviour likely to increase glucose levels.

The other differences between the groups are larger in magnitude. The mean difference in EQ-5D index of 0.13 points represents an effect of d = 0.36, equal or larger to some guidelines for a clinically meaningful effect \[[@B34]\]. This difference was equal or slightly larger than the 0.08-0.10 difference reported in similar studies in other geographies \[[@B20],[@B22]\]. This finding may be particularly important, given the established predictive relationship between EQ-5D scores and both complications and mortality in diabetes \[[@B33],[@B35]\]. The magnitude of some of the other disparities are larger still; applying the standard Cohen's d effect size guidelines \[[@B36]\], the 0.08 point difference in treatment satisfaction would be interpreted as a moderate (d = 0.44) effect, while the differences in hypoglycaemia fear are large, ranging from d = 0.82 for worry to d = 0.90 for the total score.

One finding of this study that is at odds with previous research is the relationship between HEs and HbA1c. Though few studies have investigated the connection between HEs and glycaemic control, an Asian study measuring HbA1c from blood draw found lower HbA1c among those with hypoglycaemia \[[@B24]\]. It is unclear why the findings are different, but it could be that the relationship between hypoglycaemia and glycaemic control cannot be clearly ascertained from cross-sectional analyses, and there are reasons to believe that both relationships are true under certain circumstances. Indeed, those who maintain low blood glucose are, in a sense, closer to hypoglycaemia than those whose blood glucose is consistently high, and previous research has demonstrated that individuals with lower glycosylated hemoglobin levels are indeed at greater risk of HEs \[[@B7],[@B9],[@B37],[@B38]\]. However, those who experience HEs may adjust their regimen in an attempt to prevent subsequent HEs, potentially raising their HbA1c in the process \[[@B39],[@B40]\]. It could also be that relationship between glycaemic control and HEs differs according to region due to cultural or lifestyle factors.

Another interesting finding was the location of the HEs, which were most commonly reported as happening in the context of household jobs or relaxing rather than during physical activity such as exercise or playing sports which might be expected to result in low blood glucose levels. Unfortunately, this is likely due to lack of physical activity among the sample; less than half of the sample reported one or more days in the previous month during which they exercised for 20 minutes or more, and items asking about the context of the HE referred only to the most recent episode to maximize the accuracy of the recall. If individuals exercise infrequently, they have limited opportunities to have a HE during exercise.

There are some limitations of the study that should be acknowledged. An important limitation shared by this and other real-world studies on HEs is the reliance on a sample other than a population-based probability sample; in this case a sample from an opt-in survey panel. Therefore, this sample may under- or overestimate the prevalence of HEs in the UK T2D population. This also makes it difficult to determine the extent to which the other results of the present study generalize to the broader UK T2D population, though the sample appears representative on several important characteristics. The use of the online survey panel also limited follow-up reminders to email which, along with the limited response window, likely contributed to the relatively low response rate for the follow-up waves. Another limitation is the lack of HbA1c results for the majority of the sample, which limited statistical power and raises the concern that this portion of the sample may be different in important ways from the participants who were unable to provide an HbA1c value. Finally, the analyses here are primarily cross-sectional and correlational in nature. Comparisons were not adjusted for potential differences between the groups in terms of demographic, disease, or treatment characteristics, and differences between the groups other than the presence of HEs may explain the differences in outcomes.

While not a limitation per se, an important point to consider is that HE status relied on self-report. Patient characterizations of their most recent HE revealed that many did not test blood glucose during their episode, and a few claimed to have normal blood glucose levels during their HE, raising the question of whether all those in the HE group experienced a HE as defined by the American Diabetes Association criteria \[[@B41]\]. From the standpoint of behaviour, this may not be important; if the perception that one is experiencing HEs result in less effective disease management, then whether the blood glucose level is actually low is of little importance. However, if the response to the HE is to switch the patient to a medication that has a lower risk of HEs, such a switch may not have the intended result because what the patient perceived as hypoglycaemia was something else.

Despite these caveats, the current study makes some meaningful contributions to our understanding of HEs among UK patients with T2D, estimating the four-week prevalence of HEs among those on antihyperglycaemic medication, characterizing the events, and documenting the differences between patients with and without recent HEs. Unlike previous some previous studies that included patients with type 1 diabetes, the current study focused entirely on T2D. The sample was considerably larger than the UK T2D samples in previous studies, and the survey included a broader array of patient-reported outcomes. The present study also confirms findings from other studies in other geographies regarding the relationship between HEs and impairment to work and non-work activities, satisfaction with medication, healthcare utilization, and fear of hypoglycaemia. The findings underscore the importance of considering risk of HEs when planning a patient's treatment regimen, ensuring patients are educated about HEs, and encouraging regular testing of blood glucose.

Conclusion
==========

HEs are unpleasant, relatively common among those being treated for T2D, and are feared by patients even if they have not had recent experience of one. Those who report recently experiencing ≥1 HE have worse health outcomes than those who do not. In addition to impaired outcomes such as health status and treatment satisfaction, experiencing ≥1 HE is associated with worry and performing behaviours designed to increase blood glucose, with the likely eventual result being impaired glucose control, an increased risk of complications, worsening health outcomes for the patient, and increased burden on the healthcare system. Future research should assess whether interventions aimed at reducing HEs and fear of HEs also improve outcomes.
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